Skip to main content
. Author manuscript; available in PMC: 2014 Nov 4.
Published in final edited form as: Vaccine. 2013 Sep 13;31(46):10.1016/j.vaccine.2013.09.001. doi: 10.1016/j.vaccine.2013.09.001

Figures 3.

Figures 3

DC-C patients have improved T cell proliferation after cyclophosphamide. Proliferative responses were measured by CFSE. The mean for each population is shown. OVCA=ovarian cancer patients off protocol, DC-C=dendritic cell vaccine recipients with Cytoxan, DC-NC-dendritic cell vaccine recipients without Cytoxan.